Royalty Amount. Mayo shall pay to Licensor, on a calendar quarter basis, royalties equal to six percent (6 %) of the Net Sales of Licensed Products or Licensed Services.
Royalty Amount. Within thirty (30) days following the end of each calendar quarter ending March 31, June 30, September 30 and December 31 from and after April 1, 2000, PSF shall pay to Covol quarterly royalty payments in an amount equal to (i) $** multiplied by (ii) the total dollar amount of tax credits under Section 29 of the Internal Revenue Code available to PSF as a result of sales of synthetic fuel produced by the Facility and sold by PSF during the calendar quarter just ended, regardless of whether PSF uses such tax credits; provided, however, royalty payments shall not be computed on, and no royalty payment shall be due with respect to, sales of synthetic fuel that are in excess of the "Maximum Annual Royalty Tonnage." For purposes of this Agreement, the "Maximum Annual Royalty Tonnage" is achieved in any calendar year whenever the aggregate amount of synthetic fuel produced and sold by the Facility and the Other Facilities in such calendar year equals 1,440,000 tons; provided, however, that if any of the Other Facilities is the subject of a Facility Sub License or Facility Assignment, then the Maximum Annual Royalty Tonnage shall be reduced by 360,000 tons per calendar year for each Other Facility that is the subject of a Facility Sub License or Facility Assignment; provided, further, that if the Facility is the subject of a Facility Sub License or Facility Assignment, royalty payments in any calendar year shall not be computed on, and no royalty payment shall be due with respect to, sales of synthetic fuel produced by the Facility in such calendar year in excess of 360,000 tons without regard to the volume of production and sale of synthetic fuel from the Other Facilities.
Royalty Amount. In consideration for the license granted under this Agreement, Licensee agrees to pay to Licensor a royalty in the amount of Eight percent (8%) of the Licensee’s Net Sales. “Net Sales” shall mean Licensee’s gross sales of Licensed Products, less all discounts and allowances actually given and any bona fide returns. Royalties to be paid on or before June 30 and December 15 each year.
Royalty Amount. Subject to Section 3 of this Article IV, Licensee shall pay Licensor a royalty on all Net Receipts received by Licensee in connection with the licensing or use of the Software or any Derivative Software Products in accordance with the following schedule: Royalty as a Percentage of Net Receipts Received by Licensee During the Calendar Year Applicable Calendar Year ------------- -------------------------- 1995 None 1996 15% on all Net Receipts in excess of $2,000,000.00 1997 15% on all Net Receipts 1998 15% on all Net Receipts 1999 10% on all Net Receipts 2000 5% on all Net Receipts
Royalty Amount. Subject to the terms and conditions of this Agreement, during the Royalty Term (as defined below), in partial consideration for the rights and licenses granted to Xxxxxxx by Genmab hereunder, Xxxxxxx shall make royalty payments to Genmab on annual Net Sales of Licensed Product as described in this Clause 6.5(A). Royalties due on Net Sales of Licensed Product hereunder shall be paid on a Licensed Product-by-Licensed Product and country-by-country basis, commencing on the date of the First Commercial Sale of such Licensed Product in such country and expiring on the later of: (i) thirteen (13) years thereafter; or (ii) the expiration (such expiration to occur only after expiration of extensions of any nature to such patents which may be obtained under applicable statutes or regulations in the respective countries, such as patent extension laws in countries which are similar to the Drug Price Competition and Patent Term Restoration Act of 1984 in the United States, including without limitation any supplementary protection certificates (“SPCs”)) or invalidation of the last remaining Valid Claim within the Product Patents in effect in such country that, but for the licenses granted hereunder, would be infringed by the import, use, manufacture, offer to sell or sale of a Licensed Product in the Field in such country (such period, the Royalty Term). Royalties on such Net Sales in a given Calendar Year shall be calculated as follows:
Royalty Amount. Unless otherwise agreed in writing, the per unit Royalty Amount will be set separately for each instrument as defined as Products, as specifically set forth in Exhibit A.
Royalty Amount. As partial consideration for the exclusive licenses provided herein, and subject to the limitations below, JBI shall pay to Aduro royalties on aggregate Net Sales of Licensed Immunotherapeutics for each Calendar Year during the Royalty Term, applicable on a Licensed Immunotherapeutic by Licensed Immunotherapeutic basis, as follows:
Royalty Amount. Subject to the adjustments provided for in this Section 9.3, Licensee will pay to POZEN a royalty equal to the greater of: (a) [***]% of Net Sales of any Product by Licensee or its Affiliates in any country in the Territory, and (b) the Minimum Royalty Amount for such Product in such country. [***].
Royalty Amount. Subject to the terms and conditions of this Section 3.2(b), Licensee shall pay to Satiogen a royalty equal to […***…] of Net Sales of each Licensed Product sold by Licensee and its Affiliates during the Royalty Term for such Licensed Product.
Royalty Amount. In consideration of the payment of the Purchase Price by Deerfield to Titan that was made on the Effective Date, Titan shall pay to Deerfield a royalty (the “Royalty”) equal to 2.5% of Net Sales occurring during the Royalty Term. The Parties acknowledge and agree that Titan currently has a right to receive royalties from Novartis pursuant to the Novartis Sublicense, and it is the intention of Titan and Deerfield that the transaction contemplated by this Agreement shall constitute a sale of Titan’s right to receive royalties from Novartis pursuant to the Novartis Sublicense in an amount up to the amount of the Royalty, free and clear of all Liens and rights of others (other than the security interest therein in favor of the Noteholders under and as defined in the Facility Agreement) and it is intended that the beneficial interest in and title to Titan’s right to receive royalties from Novartis pursuant to the Novartis Sublicense in an amount up to the amount of the Royalty shall not be part of Titan’s bankruptcy estate if a petition by or against Titan is filed under any bankruptcy law. If, notwithstanding such intent, such transaction is held not to be a sale, Titan hereby confirms the grant of a security interest in the royalties from Novartis pursuant to the Novartis Sublicense and the proceeds thereof pursuant to the Security Agreement, dated as of March 15, 2011, as amended, between Titan and the Noteholders (as defined in the Facility Agreement). Titan also hereby confirms the grant of a security interest in all of the collateral covered by the Security Agreement, dated as of March 15, 2011, as amended, between Titan and the Noteholders (as defined in the Facility Agreement) to secure payment of the Royalty.
